|
x
|
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
For the Quarterly Period Ended March 31, 2015
|
|
Or
|
¨
|
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
For the transition period from ________ to ___________
|
Delaware
|
13-3864870
|
(State or other jurisdiction of
|
(IRS Employer Identification. No.)
|
incorporation or organization)
|
|
|
|
660 Madison Avenue, Suite 1700
|
10065
|
New York, NY
|
(zip code)
|
(Address of principal executive offices)
|
|
|
|
|
|
|
|
|
|
|
Page No.
|
Condensed Consolidated Financial Statements
(Unaudited)
|
||
|
|
|
|
|
March 31, 2015
|
|
December 31, 2014
|
||||
ASSETS
|
|
|
|
||||
Current assets
|
|
|
|
||||
Cash and cash equivalents
|
$
|
95,545,619
|
|
|
$
|
99,713,929
|
|
Restricted cash
|
—
|
|
|
4,000,000
|
|
||
Accounts receivable
|
14,272,317
|
|
|
491,632
|
|
||
Inventory
|
14,815,835
|
|
|
19,044,477
|
|
||
Prepaid expenses and other current assets
|
422,521
|
|
|
898,705
|
|
||
Deferred tax assets
|
6,251,436
|
|
|
5,655,928
|
|
||
Total current assets
|
131,307,728
|
|
|
129,804,671
|
|
||
|
|
|
|
||||
Property, plant and equipment, net
|
753,158
|
|
|
831,936
|
|
||
Deferred costs
|
38,290,122
|
|
|
32,860,874
|
|
||
Goodwill
|
898,334
|
|
|
898,334
|
|
||
Other assets
|
1,989,520
|
|
|
1,989,520
|
|
||
Total assets
|
$
|
173,238,862
|
|
|
$
|
166,385,335
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
|
|
|
|
||||
Current liabilities
|
|
|
|
||||
Accounts payable
|
$
|
3,553,191
|
|
|
$
|
3,384,310
|
|
Accrued expenses and other current liabilities
|
3,423,697
|
|
|
2,085,995
|
|
||
Current portion of long term debt
|
—
|
|
|
1,989,948
|
|
||
Total current liabilities
|
6,976,888
|
|
|
7,460,253
|
|
||
Deferred revenue
|
13,528,961
|
|
|
81,799
|
|
||
Deferred income tax liability
|
6,500,992
|
|
|
5,900,468
|
|
||
Other liabilities
|
389,838
|
|
|
405,325
|
|
||
Liabilities subject to compromise
|
399,040,346
|
|
|
399,039,967
|
|
||
Total liabilities
|
426,437,025
|
|
|
412,887,812
|
|
||
Commitments and Contingencies (Note 14)
|
|
|
|
||||
Stockholders’ equity (Deficit)
|
|
|
|
||||
Common stock ($.0001 par value, 100,000,000 shares authorized, 53,504,296 and 53,504,296 issued and outstanding at March 31, 2015, and December 31, 2014, respectively)
|
5,351
|
|
|
5,351
|
|
||
Additional paid-in capital
|
175,940,813
|
|
|
175,483,180
|
|
||
Accumulated deficit
|
(429,144,327
|
)
|
|
(421,991,008
|
)
|
||
Total stockholders’ equity (deficit)
|
(253,198,163
|
)
|
|
(246,502,477
|
)
|
||
Total liabilities and stockholders’ equity (deficit)
|
$
|
173,238,862
|
|
|
$
|
166,385,335
|
|
|
Three Months Ended March 31,
|
||||||
|
2015
|
|
2014
|
||||
Revenues
|
|
|
|
||||
Research and development
|
$
|
1,192,092
|
|
|
$
|
549,415
|
|
|
|
|
|
||||
Operating expenses
|
|
|
|
||||
Selling, general and administrative
|
3,087,523
|
|
|
3,088,658
|
|
||
Research and development
|
2,811,181
|
|
|
2,813,456
|
|
||
Patent preparation fees
|
333,103
|
|
|
285,736
|
|
||
Total operating expenses
|
6,231,807
|
|
|
6,187,850
|
|
||
Operating loss
|
(5,039,715
|
)
|
|
(5,638,435
|
)
|
||
Decrease (increase) in fair value of common stock warrants
|
—
|
|
|
156,105
|
|
||
Interest expense
|
(253,412
|
)
|
|
(140,829
|
)
|
||
Other income, net
|
5,464
|
|
|
5
|
|
||
Reorganization items, net
|
(1,781,825
|
)
|
|
—
|
|
||
Loss before income taxes
|
(7,069,488
|
)
|
|
(5,623,154
|
)
|
||
Benefit from (provision for) income taxes
|
(83,831
|
)
|
|
2,241,295
|
|
||
Net and comprehensive income (loss)
|
$
|
(7,153,319
|
)
|
|
$
|
(3,381,859
|
)
|
Earnings (loss) per share: basic and diluted
|
$
|
(0.13
|
)
|
|
$
|
(0.06
|
)
|
Weighted average shares outstanding: basic and diluted
|
53,504,296
|
|
|
53,252,155
|
|
|
Three Months Ended March 31
|
||||||
|
2015
|
|
2014
|
||||
Cash flows from operating activities:
|
|
|
|
||||
Net income (loss)
|
$
|
(7,153,319
|
)
|
|
$
|
(3,381,859
|
)
|
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
|
|
|
|
||||
Depreciation and other amortization
|
78,778
|
|
|
91,106
|
|
||
Increase (decrease) in fair value of warrants
|
—
|
|
|
(156,105
|
)
|
||
Stock-based compensation
|
491,724
|
|
|
698,851
|
|
||
Non-cash interest expense
|
10,052
|
|
|
9,706
|
|
||
Reorganization items
|
(581,190
|
)
|
|
—
|
|
||
Changes in assets and liabilities:
|
|
|
|
||||
Accounts receivable
|
(13,780,685
|
)
|
|
371,603
|
|
||
Inventory
|
4,228,642
|
|
|
3,439,804
|
|
||
Deferred costs
|
(5,429,248
|
)
|
|
(6,593,554
|
)
|
||
Prepaid expenses and other current assets
|
442,093
|
|
|
(7,179
|
)
|
||
Other assets
|
—
|
|
|
19,513
|
|
||
Deferred income taxes, net
|
5,016
|
|
|
(2,547,479
|
)
|
||
Accounts payable, accrued expenses and other current liabilities
|
2,087,773
|
|
|
(902,264
|
)
|
||
Liabilities subject to compromise
|
379
|
|
|
—
|
|
||
Deferred revenue
|
13,447,162
|
|
|
25,561,191
|
|
||
Other liabilities
|
(15,487
|
)
|
|
(10,570
|
)
|
||
Net cash provided by (used in) operating activities
|
(6,168,310
|
)
|
|
16,592,764
|
|
||
Cash flows from investing activities:
|
|
|
|
||||
Capital expenditures
|
—
|
|
|
(14,184
|
)
|
||
Restricted cash
|
4,000,000
|
|
|
—
|
|
||
Net cash provided by (used in) investing activities
|
4,000,000
|
|
|
(14,184
|
)
|
||
Cash flows from financing activities:
|
|
|
|
||||
Net proceeds from exercise of warrants and options
|
—
|
|
|
94,675
|
|
||
Payment of common stock tendered for employee tax obligations
|
—
|
|
|
(415,938
|
)
|
||
Repayment of long-term debt
|
(2,000,000
|
)
|
|
(500,001
|
)
|
||
Net cash provided by (used in) financing activities
|
(2,000,000
|
)
|
|
(821,264
|
)
|
||
Net increase (decrease) in cash and cash equivalents
|
(4,168,310
|
)
|
|
15,757,316
|
|
||
Cash and cash equivalents at beginning of period
|
99,713,929
|
|
|
91,309,754
|
|
||
Cash and cash equivalents at end of period
|
$
|
95,545,619
|
|
|
$
|
107,067,070
|
|
|
|
|
|
|
March 31, 2015
|
|
December 31, 2014
|
||||
Deferred revenue
|
$
|
203,652,182
|
|
|
$
|
203,696,194
|
|
Accounts payable - pre-petition
|
3,568,874
|
|
|
3,502,607
|
|
||
Expectation damages accrual- PharmAthene Litigation
|
187,820,361
|
|
|
187,820,361
|
|
||
Legal and expert fees accrual - PharmAthene Litigation
|
3,226,055
|
|
(1)
|
3,226,055
|
|
||
Other accrued expenses - pre-petition
|
772,874
|
|
|
794,750
|
|
||
Total
|
$
|
399,040,346
|
|
|
$
|
399,039,967
|
|
|
March 31, 2015
|
||
Legal fees
|
$
|
1,201,792
|
|
Professional fees
|
564,496
|
|
|
Trustee fees
|
13,000
|
|
|
Other
|
2,537
|
|
|
Total
|
$
|
1,781,825
|
|
|
Three Months Ended March 31,
|
||||
|
2015
|
|
2014
|
||
Stock Options
|
2,108,967
|
|
|
2,239,793
|
|
Stock-Settled Stock Appreciation Rights
|
372,114
|
|
|
402,618
|
|
Restricted Stock Units
|
1,161,666
|
|
(1)
|
1,295,189
|
|
Warrants
|
250,000
|
|
|
1,216,226
|
|
•
|
Level 1 – Quoted prices for identical instruments in active markets.
|
•
|
Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.
|
•
|
Level 3 – Instruments where significant value drivers are unobservable to third parties.
|
|
2015
|
|
2014
|
||||
Work in-process
|
$
|
4,788,035
|
|
|
$
|
16,688,682
|
|
Finished goods
|
10,027,800
|
|
|
2,355,795
|
|
||
Inventory
|
$
|
14,815,835
|
|
|
$
|
19,044,477
|
|
|
2015
|
|
2014
|
||||
Leasehold improvements
|
$
|
3,170,598
|
|
|
$
|
3,170,598
|
|
Computer equipment
|
669,782
|
|
|
669,782
|
|
||
Furniture and fixtures
|
488,807
|
|
|
488,807
|
|
||
|
4,329,187
|
|
|
4,329,187
|
|
||
Less - accumulated depreciation
|
(3,576,029
|
)
|
|
(3,497,251
|
)
|
||
Property, plant and equipment, net
|
$
|
753,158
|
|
|
$
|
831,936
|
|
|
2015
|
|
2014
|
||||
Bonus
|
$
|
405,000
|
|
|
$
|
17,500
|
|
Professional fees
|
544,090
|
|
|
534,775
|
|
||
Vacation
|
299,904
|
|
|
271,000
|
|
||
Other
|
2,174,703
|
|
|
1,262,720
|
|
||
Accrued expenses and other current liabilities
|
$
|
3,423,697
|
|
|
$
|
2,085,995
|
|
|
|
SIGA TECHNOLOGIES, INC.
|
||
|
|
(Registrant)
|
||
|
|
|
||
Date:
|
May 6, 2015
|
By:
|
/s/ Daniel J. Luckshire
|
|
|
|
|
Daniel J. Luckshire
|
|
|
|
|
Executive Vice President and
|
|
|
|
|
Chief Financial Officer
|
|
|
|
|
(Principal Financial Officer and
|
|
|
|
|
Principal Accounting Officer)
|
1.
|
Amendments
. Upon the Amendment Effective Date (as defined below), the Agreement, shall be amended as follows:
|
1.1.
|
Article 2, clause 2.3 of the Agreement is amended by adding a new subsection 2.3.1.1 reading as follows:
|
1.2.
|
Article 4, clause 4.1 of the Agreement is amended by adding the following to the end of that clause:
|
Quantity
|
Approx Production Start
|
Approx Ship Date
|
Unit Price*
|
[redacted]
forecasted on March 16, 2015
|
[redacted]
|
[redacted]
|
1
st
4,200 kg = [redacted] per kg
Remaining [redacted] = [redacted] per kg
|
|
|
|
|
Next [redacted] kg
|
[redacted]
|
[redacted]
|
[redacted] per kg
|
|
|
|
|
Next [redacted] kg
|
[redacted]
|
[redacted]
|
[redacted] per kg
|
|
|
|
|
Any additional during Term
|
TBD
|
TBD
|
[redacted] per kg
|
1.3.
|
Article 4, clause 4.2 is deleted in its entirety and replaced with the following:
|
1.4.
|
Article 8, clause 8.1 is deleted in its entirety and replaced with the following:
|
1.5.
|
Paragraph 3 of the First Addendum is deleted.
|
2.
|
Effect
. Except as specifically amended by this 2015 Amendment, the Agreement, as amended by the First Addendum, the Second Addendum, and the Third Addendum, will remain in full force and effect. All references to the "Agreement" in the Agreement and to the “Commercial Manufacturing Agreement” in the First Addendum, the Second Addendum, and the Third Addendum, will hereafter be deemed to refer to the Agreement as amended by the Parties through and including this 2015 Amendment.
|
3.
|
Miscellaneous
.
|
3.1.
|
Effectiveness
. This 2015 Amendment and the assumption of the Agreement, as amended, shall be effective upon the entry of a non-appealable order approving the same by the Court (the “
Approval Date
”) and payment of the Invoiced Costs by wire transfer in US Dollars within five business days following the Approval Date (the “
Amendment Effective Date
”). Albemarle represents and warrants that other than the Invoiced Costs, no amounts are due under the Agreement and no other claims exist under the Agreement relating to the period prior to the date hereof, other than any amounts payable with respect to performance under the Agreement subsequent to the Petition Date.
|
3.2.
|
Definitions
. Capitalized terms used and not defined herein have the meanings given to such terms in the Agreement.
|
3.3.
|
Counterparts/ Facsimiles
. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. The parties agree that, notwithstanding any statute, regulation, decision, rule of evidence, or other law to
|
3.4.
|
Governing Law
. This Amendment will be governed by the Applicable Law provision contained in the Agreement.
|
SIGA TECHNOLOGIES, INC.
By: /s/ Daniel J. Luckshire
Title: EVP- CFO
|
ALBEMARLE CORPORATION
By: /s/Kurt Hoeprich
Title: VP-FCS
|
12. ACCOUNTING AND APPROPRIATION DATA (
If Required
)
N/A
|
|
|||||||||||
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,
IT MODIFIES THE CONTRACT/ORDER NO., AS DESCRIBED IN ITEM 14
|
|
|||||||||||
(Y)
|
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (
Specify Authority
) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
|
|||||||||||
|
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (
such as changes in paying office, appropriation date, etc.
) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103 (b).
|
|||||||||||
X
|
C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
FAR 43.103(A)(3) Bilateral - Other Agreements of the Parties
|
|||||||||||
|
D. OTHER (
Specify type of modification and authority
)
|
|||||||||||
E. IMPORTANT
: Contractor
|
[ ]
|
is NOT
|
[X]
|
is required to sign this document and return
|
1
|
copies to the issuing office.
|
|
|||||
14. DESCRIPTION OF AMENDMENT/MODIFICATION
(Organized by UCF section headings, including solicitation/contract subject matter where feasible.
PURPOSE: This modification revises section F.6. Delivery Schedule.
FUNDS ALLOTTED PRIOR TO MOD #9 $ 463,393,621.00
FUNDS ALLOTTED WITH MOD #9
$ 0.00
TOTAL FUNDS ALLOTTED TO DATE $ 463,393,621.00 (Unchanged)
EXPIRATION DATE: September 24, 2020 (Unchanged)
CONTRACT FUNDED THROUGH September 24, 2020 (Unchanged)
|
|
|||||||||||
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.
|
|
|||||||||||
15A. NAME AND TITLE OF SIGNER
Dennis E. Hruby
Chief Scientific Officer
|
16A. NAME AND TITLE OF CONTRACTING OFFICER
Linda D. Luczak, Contracting Officer
DHHS/OS/ASPR/AMCG
|
|
||||||||||
15B. CONTRACTOR/OFFEROR
/s/ Dennis E. Hruby
|
15C. DATE SIGNED
29 April 2015
|
16B. UNITED STATES OF AMERICA
/s/ Linda D. Luczak
|
16C. DATE SIGNED
4/29/2015
|
|||||||||
(Signature of person authorized to sign)
|
|
(Signature of Contracting Officer)
|
|
Contract No.
HHS0100201100001C Modification No.9 |
Continuation Sheet
Block 14 |
Page 2 of 2
|
Delivery Number
|
Number of Bottles (42 x 200mg Capsules)
|
Number of
Courses |
Delivery
Date |
Batches
|
#1
|
[redacted]*
|
[redacted]*
|
[redacted]*
|
Commercial Validation
|
#2
|
[redacted]*
|
[redacted]*
|
[redacted]*
|
Commercial
|
#3
|
[redacted]*
|
[redacted]*
|
[redacted]*
|
Commercial
|
#4
|
[redacted]*
|
[redacted]*
|
[redacted]*
|
Commercial
|
#5
|
[redacted]*
|
[redacted]*
|
[redacted]*
|
Commercial
|
#6
|
[redacted]*
|
[redacted]*
|
[redacted]*
|
Commercial
|
#7
|
[redacted]*
|
[redacted]*
|
[redacted]*
|
Commercial
|
#8
|
[redacted]*
|
[redacted]*
|
[redacted]*
|
Commercial
|
#9
|
[redacted]*
|
[redacted]*
|
[redacted]*
|
Commercial
|
#10
|
[redacted]*
|
[redacted]*
|
[redacted]*
|
Commercial
|
#11
|
[redacted]*
|
[redacted]*
|
[redacted]*
|
Commercial
|
#12
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
#13
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
#14
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
#15
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
#16
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
#17
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
#18
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
#19
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
#20
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
#21
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
#22
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
#23
|
[redacted]*
|
[redacted]*
|
TBD
|
Commercial
|
Total
|
4,000,000
|
2,000,000
|
|
|
1.
|
I have reviewed this quarterly report on Form 10-Q of SIGA Technologies, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: May 6, 2015
|
|
/s/ Eric A. Rose
|
Eric A. Rose, M.D.
|
Chairman and Chief Executive Officer
|
1.
|
I have reviewed this quarterly report on Form 10-Q of SIGA Technologies, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: May 6, 2015
|
|
/s/ Daniel J. Luckshire
|
Daniel J. Luckshire
|
Executive Vice President and
Chief Financial Officer
|
(1)
|
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
/s/ Eric A. Rose
|
Eric A. Rose, M.D.
|
Chairman and Chief Executive Officer
|
May 6, 2015
|
(1)
|
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
/s/ Daniel J. Luckshire
|
Daniel J. Luckshire
|
Executive Vice President and Chief Financial Officer
|
May 6, 2015
|